Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

AGM Statement

16 Jun 2006 07:00

Embargoed Release: 07:00hrs Friday 16th June 2006 SOPHEON PLC AGM Statement At the Annual General Meeting of Sopheon plc to be held later today, theChairman of the board will give shareholders an update on the business. Thiswill include the following statement:"We are almost at the end of the first half of 2006 and in this period we havehad steady and continued development in our business. In addition to businessgenerated in our traditional territories, we are pleased to report that we havesigned our second major Accolade sale in Scandinavia, and our first in France.Our teams in the US and Europe have been able to generate 50% moreimplementation and consulting services revenue by the end of May than in thesame period last year, thanks in part to management actions taken in the secondhalf of last year. New license wins and increased recurring maintenancerevenues - which now stand at ‚£1.6m annualized - along with the step up inservices business, has put the overall business on course to significantlyimprove on the first half of 2005. However, as always I would mention that ourperformance in any reporting period can be materially affected by the signaturedate of individual deals. This factor will be a continuing consideration as webuild the business, but one that should be increasingly offset by growth.The market for product life cycle management (PLM) applications continues toexpand, with analysts forecasting compound annual growth rates ranging from 8%to 11% through 2008. More importantly, during the same period, the PLMsubmarket in which Accolade has been classified is projected to triple in size.Sopheon's offering is well positioned to take advantage of this anticipatedescalation in demand. In 2005, we strengthened our market-share in thechemicals, paper and food & beverage industries, and they remain our principaltargets. But we have also enjoyed major successes with new clients in consumerpackaged goods markets, and recently expanded our sales and marketing effortsto target manufacturers in that sector.On the product front, we have invested in the creation of a new research andapplications development (RAD) team. Its charter is to create new softwareapplications that leverage the strength of the Accolade platform and providenew sources of revenue growth. We are pleased to announce the firstapplications produced by the RAD organization, which will be introduced to themarket in the third quarter of this year: * Accolade Product Roadmapping and Planning Application - this offering will enable companies to advance the maturity of their innovation processes by making it easier for them to develop and evaluate long-term product plans, manage programs or product "families", manage product relationships, and assess the impact of dependencies among projects during portfolio analysis. * New Versions of Accolade's Stage-Gate Process and Portfolio Management Applications - these enhanced versions of existing Accolade applications will introduce new best-practice models to further support portfolio planning and the post-launch stages of product life cycle management. One important benefit of our product strategy will be to further ourrelationships with existing clients, which accounted for a quarter ofnon-recurring revenues during 2005. We expect our partners to contribute to anincrease in lead activity and sales contracts during 2006 as our resellernetwork gains additional traction and our emerging relationships with selectglobal business-management consulting partners deepen. The importance ofSopheon's ongoing relationship with Microsoft was raised to a new level withour recent promotion to the elite status of "named" partner. This advancemententitles Sopheon to the support of a Microsoft business development managerdedicated to ensuring that we receive maximum business benefit from our accessto Microsoft technical, sales and marketing resources.Sopheon also announces that it has filed a certification with the US Securitiesand Exchange Commission ("SEC") on Form 15, to immediately suspend its duty tofile reports under the Securities Act of 1934. Sopheon will realize costsavings by no longer making these filings. The certification confirms, amongother points, that Sopheon has approximately 400 US resident shareholders.These shareholders represent less than 1% of the company's issued capital, andSopheon's ordinary shares are not traded in any US markets. Sopheon beganfiling reports with the SEC following its US registration of shares issued inconnection with the acquisition of Teltech Resource Network Corporation in2000. This change will have no effect on the trading of Sopheon's shares on AIMand Euronext.Finally, we wish to inform you that Andrew Davis, a non-executive director, isretiring from the board of Sopheon as from 30 June 2006, in order to focus onhis other interests. The directors and staff thank him for his contribution tothe development of the group. This brings the overall size of the Sopheon boardto six, comprising three executive and three non-executive directors."For further information contact:Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO Adam Reynolds Hansard Communications Tel : + 44 (0) 207 245 1100 Andrew Tan + 44 (0) 7957 203 685 Frank Jansen Citigate First Financial Tel : + 31 (0) 205 75 40 24 About SopheonSopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product innovation. TheSopheon Accolade‚® system automates gate or phase-based product developmentprocesses and provides strategic decision support that allows companies toincrease revenue and profits from new products. Sopheon is listed on the AIMMarket of the London Stock Exchange and on the Euronext in the Netherlands. Formore information, please visit www.sopheon.com.ENDSOPHEON PLC
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.